Avalo Therapeutics reports 2025 net loss of $78.3M; Phase 2 HS topline data due Q2 2026

Avalo Therapeutics, Inc.

Net loss $78.3M ($5.84 per share) vs $35.1M in 2024; operating expenses rose to $73M.
Cash, equivalents and short-term investments $98.3M as of Dec 31, 2025; expected runway into 2028.
R&D expenses $50.1M, up $25.6M YoY driven by Phase 2 LOTUS trial costs for abdakibart (AVTX-009).
Topline data from Phase 2 abdakibart trial for hidradenitis suppurativa expected in Q2 2026.
G&A expenses $22.9M, up $5.7M primarily from stock-based compensation and headcount additions.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Avalo Therapeutics, Inc. reported the year ended December 31, 2025 results: net income Net loss was $78.3 million for the year ended December 31, 2025, EPS Basic and diluted net loss per share was $5.84 for the year-ended December 31, 2025.

Period: the year ended December 31, 2025
Net income: Net loss was $78.3 million for the year ended December 31, 2025
EPS: Basic and diluted net loss per share was $5.84 for the year-ended December 31, 2025
Result: reported results

Exact text from the filing

On March 23, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001534120-26-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.